DoD Autism Clinical Translational Research Award | W81XWH 18 ARP CTRA

FAQs: DoD Autism Research Program (ARP) Clinical Translational Research Award (CTRA)

What is the ARP Clinical Translational Research Award (CTRA)?

The Autism Research Program (ARP) Clinical Translational Research Award (CTRA) is a Department of Defense funding opportunity intended to move promising autism spectrum disorder (ASD) interventions closer to real-world clinical impact. It supports early-phase, proof-of-principle translational studies that can generate initial clinically relevant evidence and set the stage for later, larger-scale efficacy trials.

What is the main purpose of this award?

The main purpose is to bridge the gap between discovery and practice in ASD by funding hypothesis-driven, early clinical translational work that can change standards of clinical care over time. The program emphasizes producing actionable outcomes that justify and inform subsequent definitive clinical testing, rather than generating purely exploratory findings.

What kind of research does the CTRA emphasize?

The CTRA emphasizes early-phase, proof-of-principle translational studies that are hypothesis-driven and focus on innovative interventions with clear potential to reduce current clinical deficits in ASD. The intent is to create an evidence base that is clinically oriented (for example, early signals of benefit, feasibility, acceptability, or optimized delivery approaches) and suitable for launching later efficacy trials.

Is this opportunity focused on basic research or clinical impact?

It is focused on clinical impact. The award is designed to support translational work that produces results usable for clinical decision-making and future trials, with the long-term aim of changing ASD clinical care standards rather than supporting purely exploratory or discovery-only research.

What does "clinical translational" mean in this context?

In this opportunity, "clinical translational" refers to research that translates promising interventions toward real-world use by generating early clinical or clinically oriented evidence. This can include outcomes like early signals of clinical benefit, feasibility and acceptability, and optimization of how an intervention is delivered to support future, definitive clinical testing.

What are the expected outcomes or deliverables from funded projects?

Funded projects are expected to produce actionable translational outcomes such as early signals of clinical benefit, feasibility and acceptability data, optimization of intervention delivery, and other results that provide a strong scientific rationale for later, larger, well-powered clinical trials.

Does the program require alignment with specific Areas of Interest?

Applicants are strongly encouraged to align proposals with one or more established Areas of Interest. However, projects outside those topics may still be considered if the application clearly explains how the work addresses a critical unmet need for the ASD community.

If a project is outside the listed Areas of Interest, can it still be competitive?

Yes. The summary indicates that projects outside the Areas of Interest may still be considered, as long as the application clearly explains how it addresses a critical unmet need for the ASD community and remains consistent with the translational, actionable focus of the award.

What types of interventions are within scope?

The Areas of Interest include a wide range of intervention types, such as behavioral, cognitive, and other non-pharmacological therapies; pharmacological, genetic, or other biological treatments targeting ASD; and work related to environmental risk factors. The emphasis is on interventions that can meaningfully reduce current clinical deficits and move toward clinical application.

Does the CTRA include dissemination and implementation research?

Yes. The opportunity prioritizes dissemination and implementation research that helps clinically validated interventions reach broader use in typical care settings, not only specialized research clinics.

Is research on co-occurring conditions in ASD included?

Yes. A major focus includes treatment of co-occurring conditions that often drive impairment and caregiver burden in ASD.

Which co-occurring conditions are specifically highlighted?

The summary highlights sleep problems, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit symptoms, and seizures as co-occurring conditions of interest.

Does the opportunity support research focused on transition to adulthood?

Yes. Additional priorities include interventions that support successful transitions into adulthood for individuals with ASD.

Are projects aimed at improving healthcare provider training and ASD care delivery included?

Yes. The Areas of Interest include tools or training aimed at healthcare providers to improve ASD care across the lifespan and across care contexts, including primary care, urgent and emergency care, and disaster relief.

Is improving ASD diagnosis across the lifespan part of the Areas of Interest?

Yes. The opportunity includes efforts to improve diagnosis across the lifespan as a stated priority area.

Does the program address cultural and socioeconomic factors in ASD care?

Yes. The summary notes research addressing cultural and socioeconomic factors that influence treatment effectiveness, access, and service delivery as an additional priority.

Who is offering this funding opportunity?

The opportunity is offered by the Department of Defense, Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

What is the funding opportunity number and CFDA number?

The funding opportunity number is W81XWH 18 ARP CTRA, and it falls under CFDA 12.420.

How is this opportunity categorized?

It is categorized as science and technology and other research and development.

What funding instruments are available under this opportunity?

The listed funding instruments include both grants and cooperative agreements. This suggests that some awards may involve substantial agency involvement or coordination expectations, depending on the specific mechanism used.

What does it mean that cooperative agreements may be used?

Based on the summary, cooperative agreements indicate that some awards may involve substantial agency involvement or coordination expectations compared with standard grants, depending on the mechanism selected for an award.

Who is eligible to apply?

Eligibility is described as unrestricted, meaning a broad range of organizations may apply, subject to any additional eligibility instructions that would appear in the full announcement.

How many awards are expected?

The posting indicates an expected two awards.

When was the opportunity released and when did it close?

The original opportunity was released on May 21, 2018, and the original closing date was October 4, 2018.

Is there a stated maximum award amount (ceiling) in the provided summary?

No. The provided summary shows an award ceiling as 0, which typically indicates that the ceiling was not stated in this summary and that applicants would need to refer to the full solicitation for budget limits, project period guidance, and cost rules.

What is the long-term goal of the CTRA program?

The long-term goal is to support research that can ultimately change standards of ASD clinical care by generating early translational evidence that leads to larger, definitive efficacy trials and broader real-world clinical impact.